Clinical trial
Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC
NCT00026624 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00026624 |
|---|---|
| Title | Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC |
| Official title | A Phase I/II Study to Evaluate the Safety and Immunogenicity of the Subcutaneous Administration of ALVAC-HIV vCP1452 Infected Autologous Dendritic Cells Versus the Subcutaneous Administration of ALVAC-HIV vCP1452 To HIV-Infected Subjects |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Biological, Drug |
| Interventions | ALVAC(2)120(B, MN)GNP (vCP1452), Keyhole-Limpet Hemocyanin |
| Completion | Oct 1, 2006 |
| First posted | Nov 13, 2001 |
| Last update posted | Nov 1, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: